Our Sciences
From Biomarker Discovery to Clinical Practice
For biomarker discovery and development, our core technology is the “un-targeted and targeted mass spectrometry proteomics”. We used different methodology or research tools to develop the prototype of an assay based on the physical/chemical property of different biomarkers themselves.
Why Exosomes - Small Extracellular Vesicle (sEV) ?
Exosomes are cell-derived nanovesicles containing heterogeneous active biomolecules such as proteins, lipids, mRNAs, receptors, immune regulatory molecules, and nucleic acids. They typically range in size from 30 to 150 nm in diameter. Exosomes function like a natural toolbox and could carry cargos (protein, mRNA …) from original cells to distant cells. Exosomes mediate intercellular communication, enabling the transfer biological signals from the donor cells to the recipient cells.
There is a need for the establishment of standardized isolation and characterization methods in the exosome (Extracellular Vesicles) study. For clinical utility, exosomes require new isolation and analysis tools.
Exosome Isolation / Characterization
ExoNox Has Developed an Optimized Protocol for Exosome Biomarker Discovery in Plasma
- Size exclusion chromatography (qEV) + Ultracentrifugation
- Fractionation, sorting
- QC of exosome fraction
- qNano Gold: Particle size distribution
- Western Blotting: exosomal markers
- Exosome Proteomic Analysis
- Nano LC-MS/MS
- Isobaric Tag Labeling
Intellectual Property
ExoNox’s Intellectual Property Portfolio Include
Publication
- Liu, Y.-C., Huang, Y.-T., & Chen, C.-J. (2022). Development of a high-ph reversed-phase well plate for peptide fractionation and deep proteome analysis of cells and exosomes. Analytical and Bioanalytical Chemistry, 414(7), 2513–2522.
- Chen, C.-J., Chou, C.-Y., Shu, K.-H., Chen, H.-C., Wang, M.-C., Chang, C.-C., Hsu, B.-G., Wu, M.-S., Yang, Y.-L., Liao, W.-L., Yang, C., Hsiao, Y.-T., & Huang, C.-C. (2021). Discovery of Novel Protein Biomarkers in Urine for Diagnosis of Urothelial Cancer Using iTRAQ Proteomics. Journal of Proteome Research, 20(5), 2953–2963.
- Chen, C.-J., Liao, W.-L., Chang, C.-T., Lin, Y.-N., & Tsai, F.-J. (2018). Identification of Urinary Metabolite Biomarkers of Type 2 Diabetes Nephropathy Using an Untargeted Metabolomic Approach. Journal of Proteome Research, 17(11), 3997–4007.
- Chen, C.-J., Liao, W.-L., Chang, C.-T., Liao, H.-Y., & Tsai, F.-J. (2018). Urine proteome analysis by C18 plate–matrix-assisted laser desorption/ionization time-of-flight mass spectrometry allows noninvasive differential diagnosis and prediction of diabetic nephropathy. PLOS ONE, 13(7).
- Chang, C.-T., Liao, H.-Y., Chang, C.-M., Chen, C.-Y., Chen, C.-H., Yang, C.-Y., Tsai, F.-J., & Chen, C.-J. (2013). Oxidized ApoC1 on MALDI-TOF and glycated-ApoA1 band on gradient gel as potential diagnostic tools for atherosclerotic vascular disease. Clinica Chimica Acta, 420, 69–75.